首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Pharmacokinetics (PK) and exposure-response (E-R) analysis of Kadcyla (K) as a single agent or in combination with Perjeta (P) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease

【24h】

Pharmacokinetics (PK) and exposure-response (E-R) analysis of Kadcyla (K) as a single agent or in combination with Perjeta (P) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease

机译：Kadcyla（K）作为单药或与Perjeta（P）结合使用对患有以下疾病的人类表皮生长因子受体2阳性（HER2 +）转移性乳腺癌（MBC）患者的药代动力学（PK）和暴露反应（ER）分析尚未接受过转移性疾病的化疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2016年第suppla期|共1页
作者
Lu Dan; Li Chunze; Polhamus Daniel; French Jonathan; Riggs Matthew; Agarwal Priya; Chen Shang-Chiung; Wang Xin; Smitt Melanie; Patre Monika; Strasak Alexander; Chernyukhin Nataliya; Quartino Angelica; Jin Jin Yan; Girish Sandhya;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
专利

1. Pharmacokinetics (PK) and exposure-response (E-R) analysis of Kadcyla (K) as a single agent or in combination with Perjeta (P) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease [J] . Lu Dan, Li Chunze, Polhamus Daniel, Journal of pharmacokinetics and pharmacodynamics . 2016,第Suppla期

机译：Kadcyla（K）作为单药或与Perjeta（P）结合使用对患有以下疾病的人类表皮生长因子受体2阳性（HER2 +）转移性乳腺癌（MBC）患者的药代动力学（PK）和暴露反应（ER）分析尚未接受过转移性疾病的化疗
2. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study [J] . BachelotT., BourgierC., CropetC., Journal of Clinical Oncology . 2012,第22期

机译：依维莫司联合他莫昔芬用于激素受体阳性，人表皮生长因子受体2-阴性转移性乳腺癌且事先接触芳香酶抑制剂的患者的随机II期试验：一项GINECO研究
3. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study [J] . Shannon Puhalla, Sharon Wilks, Adam M Brufsky, Breast Cancer: Targets and Therapy . 2016,第1期

机译：先前的曲妥珠单抗联合甲磺酸艾瑞布林加曲妥珠单抗作为人表皮生长因子受体2阳性局部复发或转移性乳腺癌的一线治疗的临床效果：II期，单臂，多中心研究的结果
4. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
5. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II single-arm multicenter study [O] . Shannon Puhalla, Sharon Wilks, Adam M Brufsky, 2016

机译：先前的曲妥珠单抗联合甲磺酸埃里布林联合曲妥珠单抗作为人表皮生长因子受体2阳性局部复发或转移性乳腺癌的一线治疗的临床效果：II期单臂多中心研究的结果
6. Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [O] . 2016

机译：eribulin和trastuzumab的长期联合化疗治疗3例人类表皮生长因子受体2阳性转移性乳腺癌

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号